ÂÜÀòÂÒÂ×

Tommy Broudy is a passionate biotech executive with a 20+ year track record building and growing companies in life science tools, diagnostics and therapeutics. As Operating Partner, he works with portfolio companies to create value, set strategy, build teams, establish partnerships, achieve milestones, and generate successful outcomes for all stakeholders.

Tommy was part of the leadership team for Bridgewest Group portfolio companies Molecular Response and BioDuro-Sundia and has rejoined at the investment group level. Most recently, Tommy was CEO of January Therapeutics, which develops nanoparticle technology for drug delivery. Prior, he served as Executive Vice President, Corporate Development & Marketing at BioDuro-Sundia, where he led the go to market strategy for the global CRO/CDMO. His team created a robust deal pipeline with multiple major partnerships in pharma and biotech. At Crown Bioscience, he led the US preclinical oncology operation up to the company's IPO. He cofounded and served as CSO of Molecular Response, a patient-derived tumor modeling company, up to the company's exit and strategic acquisition. At AltheaDx, he led the Business Development team to partner gene expression-based companion diagnostics for oncology therapeutics.

Tommy held postdoctoral appointments at Rockefeller University and Stanford University studying host/microbial genomics. He earned his PhD at Rockefeller in the Laboratory of Bacterial Pathogenesis and Immunology.